Literature DB >> 3780818

Long-term treatment with oral nifedipine plus theophylline in the management of chronic bronchial asthma.

C Spedini, C Lombardi.   

Abstract

The effect on bronchial smooth muscle of slow release theophylline plus placebo and theophylline plus slow release nifedipine administered for a prolonged period to 12 asthmatic and hypertensive patients has been studied. Both combinations led to a significant improvement in respiratory function parameters when compared to baseline values. No additional improvement in pulmonary function was found on long term treatment with theophylline plus nifedipine. A reduction in the number of asthmatic attacks, in the use of inhaled beta 2-agonists and better control of arterial blood pressure resulted from use of theophylline plus nifedipine. That drug combination is safe and valuable in patients with chronic bronchial obstruction and cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3780818     DOI: 10.1007/bf00870996

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

1.  Calcium antagonists in COPD.

Authors:  C Spedini; C Lombardi
Journal:  Chest       Date:  1986-02       Impact factor: 9.410

2.  Effect of nifedipine on bronchomotor tone and histamine reactivity in asthma.

Authors:  D O Williams; P J Barnes; H P Vickers; M Rudolf
Journal:  Br Med J (Clin Res Ed)       Date:  1981-08-01

3.  Oral nifedipine in chronic cor pulmonale secondary to severe chronic obstructive pulmonary disease (COPD).

Authors:  C Sturani; L Bassein; M Schiavina; G Gunella
Journal:  Chest       Date:  1983-08       Impact factor: 9.410

4.  Effect of calcium entry blockade on ethanol-induced changes in bronchomotor tone.

Authors:  C Lombardi; C Spedini; S Govoni
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

  4 in total
  1 in total

1.  Verapamil in the prophylaxis of bronchial asthma. Is the bronchoprotective effect related to the plasma level?

Authors:  E Imhof; S Elsasser; B Rosmus; H R Ha; F Follath; A P Perruchoud
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.